Saturday 17 October 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.06
0.18
−4.25%
Follow BOLT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.97 | 1.33 | 1.04 | 1.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.05) | (1.43) | (0.85) | (1.00) | |
P/B ratio |
0.32 | 0.39 | 0.34 | 0.52 | |
Price to Tangible BV |
0.32 | 0.39 | 0.34 | 0.52 | |
EV/Sales |
(0.31) | 0.35 | 0.47 | 1.54 | |
EV/EBITDA |
0.04 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.03 | (0.07) | (0.09) | (0.23) | |
EV/FCF |
0.03 | (0.07) | (0.09) | (0.24) | |
Quick Ratio |
3.28 | 3.28 | 3.14 | 2.26 | |
Current Ratio |
3.57 | 3.59 | 3.51 | 2.61 | |
Net Debt/EBITDA |
1.57 | 1.08 | 0.50 | (0.09) | |
Debt/Assets |
32.11% | 35.48% | 40.29% | 45.94% | |
Debt/Equity |
0.65 | 0.76 | 0.98 | 1.47 | |
Asset Turnover |
0.06 | 0.10 | 0.10 | 0.08 | |
Operating CF/Net income |
1.36 | 1.08 | 1.11 | 0.85 | |
Capex/Depreciation |
(0.45) | 0.00 | 0.20 | 7.16 | |
Research and Development Expense of Revenue |
301.29% | 199.52% | 18,573.08% | 102,980.00% | |
Selling, General and Administrative Expense of Revenue |
153.85% | 124.68% | 10,761.54% | 48,440.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
18.76% | 41.64% | 2,096.15% | 11,040.00% | |
Graham Net Nets |
0.26 | 0.00 | (0.36) | (1.10) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(420.68%) | (325.78%) | (404.21%) | (427.01%) | |
Free Cash Flow Yield |
(452.86%) | (380.87%) | (509.03%) | (473.38%) | |
Revenue per Share |
1.13 | 1.34 | 0.02 | 0.00 | |
Operating CF per Share |
(5.07) | (3.83) | (4.78) | (3.87) | |
Capex per Share |
(0.04) | 0.00 | 0.02 | 0.40 | |
Free Cash Flow per Share |
(5.11) | (3.83) | (4.76) | (3.47) | |
Cash per Share |
17.04 | 14.82 | 13.75 | 10.53 | |
Shareholders Equity per Share |
16.73 | 14.17 | 11.80 | 7.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.73 | 14.17 | 11.80 | 7.47 | |
Free Cash Flow |
(9.80) | (7.16) | (7.99) | (5.87) | |
Working Capital |
25.64 | 21.83 | 18.41 | 12.70 | |
Capital Expenditures |
(0.07) | 0.00 | 0.03 | 0.67 | |
Net Current Asset Value |
2.65 | 0.02 | (2.45) | (7.14) | |
EV/EBIT |
0.03 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.00 | (1.19) | (134.60) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.50 | 1.48 | 1.64 | 1.36 | |
Average Assets |
87.19 | 78.19 | 66.94 | 57.92 | |
Average Common Equity |
52.07 | 41.85 | 33.32 | 25.74 |
Columns are period end dates